26 Jul Instil Bio
Zachary Robert, M.D., Ph.D., Chief Medical Officer
Oct. 12 | 5:45pm | UBC Ballroom
Instil Bio is a clinical-stage biopharmaceutical company focused on developing an innovative cell therapy pipeline of autologous TIL therapies for the treatment of patients with cancer (solid tumors). Using an optimized and scalable manufacturing process, Instil is advancing its lead TIL product candidate, ITIL-168, for the treatment of advanced melanoma. TIL therapy is derived from lymphocytes extracted from a patient’s tumor tissue. These lymphocytes are expanded ex vivo to create a polyclonal T cell therapy that can recognize a broad set of antigens unique to each patient’s cancer. In 2022, Instil received clearance of an IND and plans to initiate a Phase I trial of ITIL-168 in additional indications targeting areas of unmet medical need, including non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), and cervical cancer. Instil is also advancing ITIL-306, a genetically engineered Costimulatory Antigen Receptor TIL (CoStAR-TIL) therapy designed to enhance the activity of TILs.